March 16, 2026
Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide d...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide d...
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck Newsroom
Scope: Industry
Related coverage
More related coverage
Press releaseMar 20, 2026Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipelineProposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,…
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epi...
Financial Tear Sheet
Financial Tear Sheet – Bausch Health Companies Inc.
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 w...
Chugai Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan
Application filed in Japan for the medical device component (ocular implant and ancillary devices) i...